The Blood and Marrow Transplant Clinical Trials Network - Data Coordinating Center (U24 Clinical Trial Not Allowed)

The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with RO I-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed.
Categories: Education, Health.